Aripiprazole (Abilify) vs Brexpiprazole (Rexulti)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline
Aripiprazole (Abilify)
Marketed by Otsuka Holdings and partners
NCT00712686 · Phase 3 · completed
A randomised, double-blind, active-controlled trial of aripiprazole (n=355) against olanzapine (n=348) in acute schizophrenia, with two co-primary objectives. The published results are mixed: olanzapine was statistically superior on PANSS efficacy at week 6, so aripiprazole did not show non-inferiority, while aripiprazole caused significantly less weight gain at week 26. The registry has no posted results; the figures are from the publication (Fleischhacker et al., Biol Psychiatry 2009).
Next expected readout: July 2030 · NCT06969755 (registry estimate)
Reported efficacy
The mean change in the PANSS Total Score (from baseline to Week 6); The percentage of patients showing significant weight gain (a≥ 7% increase) (from baseline to Week 26): Mean change in PANSS Total Score from baseline to Week 6: aripiprazole -24.6 vs olanzapine -29.5 (random regression model); treatment difference 4.9 points, 95% CI 2.2-7.6, exceeding the pre-specified 6-point non-inferiority margin -- aripiprazole did not reach non-inferiority (olanzapine was statistically superior). Aripiprazole showed significantly less weight gain at Week 26: +0.13 kg vs +4.30 kg for olanzapine, and fewer patients with significant weight gain (21% vs 40%, p<.05). (mixed)
Result source: NCT00712686
Brexpiprazole (Rexulti)
Marketed by Otsuka Holdings and partners
NCT01393613 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 674 patients with acute schizophrenia, using a validated symptom-severity scale (PANSS) as the primary measure. The pooled comparison of the two higher doses against placebo reached statistical significance (p=0.0093), and the 4 mg dose was significant on its own (p=0.0022), but the 1 mg and 2 mg doses individually did not separate from placebo, so the result was only partially met.
Next expected readout: August 2027 · NCT07742280 (registry estimate)
Reported efficacy
Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score: Change from baseline to Week 6 in PANSS total score: brexpiprazole -22.8 (SE 1.5) vs placebo -17.4 (SE 1.6); least-squares mean difference -5.33, 95% CI -9.55 to -1.10, p=0.014 (met)
Result source: NCT03198078
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aripiprazole (Abilify) | Brexpiprazole (Rexulti) |
|---|---|---|
| PANSS total, change | -26.7 vs -21.2−5.5 vs placeboNCT0010206331 other results
| -16.6 vs -13.5−3.1 vs placeboNCT0139361371 other results
|
| CGI-S, change | -1.2 vs -0.9−0.3 vs placeboNCT0010206332 other results
| -1.0 vs -0.8−0.2 vs placeboNCT0139361371 other results
|
| PANSS response | —Not posted · NCT03485417 | 38.5% vs 31.7%+6.8 vs placeboNCT013936138 other results
|
| PSP, change | —Not posted · NCT03485417 | 10.5 vs 8.5+2 vs placeboNCT0139361317 other results
|
| Relapse (% of patients) | 19.4% vs 37.5%−18.1 vs placeboNCT011496551 other result
| 13.5% vs 38.5%−24.9 vs placeboNCT01668797 |
PANSS total, change
- Aripiprazole (Abilify)
- -26.7 vs -21.2−5.5 vs placeboNCT00102063
31 other results
- -28.6 vs -21.2 NCT00102063
- -19.4 vs -22.9 NCT02054702
- -1.3 vs 4.8 NCT01149655
- -1.2 vs 4.7 NCT01149655
- -1.0 vs 4.7 NCT01149655
- -1.0 vs 4.8 NCT01149655
- -1.0 vs 4.9 NCT01149655
- -1.1 vs 4.9 NCT01149655
- -0.9 vs 5.1 NCT01149655
- -0.8 vs 5.2 NCT01149655
- -0.6 vs 5.4 NCT01149655
- -1.1 vs 5.8 NCT01149655
- -1.0 vs 6.2 NCT01149655
- -1.0 vs 5.6 NCT01149655
- -0.8 vs 5.7 NCT01149655
- -0.9 vs 5.8 NCT01149655
- -0.4 vs 5.9 NCT01149655
- -0.3 vs 6.1 NCT01149655
- -0.6 vs 6.1 NCT01149655
- -0.7 vs 5.6 NCT01149655
- -0.8 vs 5.6 NCT01149655
- -0.2 vs 5.5 NCT01149655
- -0.2 vs 4.5 NCT01149655
- -1.2 vs 3.9 NCT01149655
- -1.6 vs 3.7 NCT01149655
- -1.2 vs 2.9 NCT01149655
- -0.6 vs 1.6 NCT01149655
- -0.4 vs 1.8 NCT01149655
- 0.1 vs -0.6 NCT01149655
- 0.2 vs -0.3 NCT01149655
- -7.7 vs -9.3 NCT00216476
- Brexpiprazole (Rexulti)
- -16.6 vs -13.5−3.1 vs placeboNCT01393613
71 other results
- -20.7 vs -12.0 NCT01396421
- -14.9 vs -7.6 NCT01451164
- -14.1 vs -11.9 NCT01393613
- -14.0 vs -6.6 NCT01451164
- -13.1 vs -11.1 NCT01393613
- -12.3 vs -5.7 NCT01451164
- -10.7 vs -8.9 NCT01393613
- -11 vs -6 NCT01451164
- -8.7 vs -6.6 NCT01393613
- -7.9 vs -4.5 NCT01451164
- -4.3 vs -3.5 NCT01393613
- -4.6 vs -3.1 NCT01451164
- -20 vs -13.5 NCT01393613
- -19.6 vs -12.0 NCT01396421
- -11.5 vs -7.6 NCT01451164
- -17.3 vs -11.9 NCT01393613
- -11.1 vs -6.6 NCT01451164
- -15.6 vs -11.1 NCT01393613
- -11.2 vs -5.7 NCT01451164
- -12.6 vs -8.9 NCT01393613
- -9.4 vs -6 NCT01451164
- -8.4 vs -6.6 NCT01393613
- -6.8 vs -4.5 NCT01451164
- -5.6 vs -3.5 NCT01393613
- -3.4 vs -3.1 NCT01451164
- -16.9 vs -13.5 NCT01393613
- -8.3 vs -7.6 NCT01451164
- -14.5 vs -11.9 NCT01393613
- -8.1 vs -6.6 NCT01451164
- -14.0 vs -11.1 NCT01393613
- -8.4 vs -5.7 NCT01451164
- -11.6 vs -8.9 NCT01393613
- -6.9 vs -6 NCT01451164
- -7.6 vs -6.6 NCT01393613
- -5.1 vs -4.5 NCT01451164
- -3.3 vs -3.5 NCT01393613
- -2.7 vs -3.1 NCT01451164
- -14.9 vs -12.0 NCT01396421
- -22.8 vs -17.4 NCT03198078
- -20 vs -15.9 NCT01810380
- -22.9 vs -19.4 NCT02054702
- -17.9 vs -10.8 NCT01396421
- -14.1 vs -8.9 NCT01396421
- -11.1 vs -7.6 NCT01396421
- -8.9 vs -5.1 NCT01396421
- -4.9 vs -2.9 NCT01396421
- -18.6 vs -10.8 NCT01396421
- -16.5 vs -8.9 NCT01396421
- -12.8 vs -7.6 NCT01396421
- -9.5 vs -5.1 NCT01396421
- -4.4 vs -2.9 NCT01396421
- -11.9 vs -10.8 NCT01396421
- -8.9 vs -8.9 NCT01396421
- -5.7 vs -7.6 NCT01396421
- -3.3 vs -5.1 NCT01396421
- -2.5 vs -2.9 NCT01396421
- 0.6 vs 6.9 NCT01668797
- 3.3 vs 11.2 NCT01668797
- -2.7 vs 3.3 NCT01668797
- 2.5 vs 10.5 NCT01668797
- -1.9 vs 2.9 NCT01668797
- 1.6 vs 9.2 NCT01668797
- 0.8 vs 6.2 NCT01668797
- 1.6 vs 6.6 NCT01668797
- 0.8 vs 4.1 NCT01668797
- 0.5 vs 3.6 NCT01668797
- -9.8 vs -14.4 NCT00905307
- -18.7 vs -14.4 NCT00905307
- -16.2 vs -14.4 NCT00905307
- -18.3 vs -14.4 NCT00905307
- -3.7 vs -0.3 NCT03526354
CGI-S, change
- Aripiprazole (Abilify)
- -1.2 vs -0.9−0.3 vs placeboNCT00102063
32 other results
- -1.3 vs -0.9 NCT00102063
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.4 NCT01149655
- 0.1 vs 0.4 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.0 vs 0.2 NCT01149655
- 0.0 vs 0.1 NCT01149655
- 0.0 vs 0.1 NCT01149655
- 0.0 vs 0.1 NCT01149655
- 0 vs 0.0 NCT01149655
- 0.0 vs 0.0 NCT01149655
- -0.8 vs -0.5 NCT01795547
- -1.3 vs -1.6 NCT02054702
- -0.1 vs -0.3 NCT00216476
- Brexpiprazole (Rexulti)
- -1.0 vs -0.8−0.2 vs placeboNCT01393613
71 other results
- -1.1 vs -0.8 NCT01396421
- -0.8 vs -0.6 NCT01451164
- -0.8 vs -0.7 NCT01393613
- -1.0 vs -0.7 NCT01396421
- -0.8 vs -0.5 NCT01451164
- -0.7 vs -0.6 NCT01393613
- -0.7 vs -0.5 NCT01396421
- -0.6 vs -0.4 NCT01451164
- -0.6 vs -0.4 NCT01393613
- -0.6 vs -0.5 NCT01396421
- -0.5 vs -0.4 NCT01451164
- -0.4 vs -0.4 NCT01393613
- -0.4 vs -0.3 NCT01396421
- -0.4 vs -0.3 NCT01451164
- -0.2 vs -0.1 NCT01393613
- -0.2 vs -0.1 NCT01396421
- -0.2 vs -0.1 NCT01451164
- -1.2 vs -0.8 NCT01393613
- -1.2 vs -0.8 NCT01396421
- -0.6 vs -0.6 NCT01451164
- -1.0 vs -0.7 NCT01393613
- -1.1 vs -0.7 NCT01396421
- -0.6 vs -0.5 NCT01451164
- -0.8 vs -0.6 NCT01393613
- -1.0 vs -0.5 NCT01396421
- -0.5 vs -0.4 NCT01451164
- -0.7 vs -0.4 NCT01393613
- -0.7 vs -0.5 NCT01396421
- -0.5 vs -0.4 NCT01451164
- -0.4 vs -0.4 NCT01393613
- -0.5 vs -0.3 NCT01396421
- -0.3 vs -0.3 NCT01451164
- -0.2 vs -0.1 NCT01393613
- -0.2 vs -0.1 NCT01396421
- -0.1 vs -0.1 NCT01451164
- -0.9 vs -0.8 NCT01393613
- -0.5 vs -0.6 NCT01451164
- -0.8 vs -0.7 NCT01393613
- -0.5 vs -0.5 NCT01451164
- -0.7 vs -0.6 NCT01393613
- -0.5 vs -0.4 NCT01451164
- -0.6 vs -0.4 NCT01393613
- -0.4 vs -0.4 NCT01451164
- -0.3 vs -0.4 NCT01393613
- -0.3 vs -0.3 NCT01451164
- -0.1 vs -0.1 NCT01393613
- -0.1 vs -0.1 NCT01451164
- -0.8 vs -0.8 NCT01396421
- -0.7 vs -0.7 NCT01396421
- -0.6 vs -0.5 NCT01396421
- -0.3 vs -0.5 NCT01396421
- -0.2 vs -0.3 NCT01396421
- -0.1 vs -0.1 NCT01396421
- -0.2 vs 0.3 NCT01668797
- 0.0 vs 0.6 NCT01668797
- -0.3 vs 0.3 NCT01668797
- 0 vs 0.6 NCT01668797
- -0.2 vs 0.2 NCT01668797
- -0.0 vs 0.5 NCT01668797
- -0.0 vs 0.4 NCT01668797
- -0.0 vs 0.3 NCT01668797
- -0.9 vs -0.8 NCT03198078
- -0.0 vs 0.3 NCT01668797
- -0.1 vs 0.2 NCT01668797
- -1.2 vs -0.9 NCT01810380
- -1.6 vs -1.3 NCT02054702
- -0.4 vs -0.8 NCT00905307
- -1.0 vs -0.8 NCT00905307
- -0.9 vs -0.8 NCT00905307
- -1.1 vs -0.8 NCT00905307
- -0.3 vs -0.1 NCT03526354
PANSS response
- Aripiprazole (Abilify)
- —Not posted · NCT03485417
- Brexpiprazole (Rexulti)
- 38.5% vs 31.7%+6.8 vs placeboNCT01393613
8 other results
- 49.7% vs 31.7% NCT01393613
- 43.6% vs 31.7% NCT01393613
- 43.6% vs 28.2% NCT03198078
- 48.7% vs 32.1% NCT01810380
- 40.5% vs 49.5% NCT00905307
- 57.3% vs 49.5% NCT00905307
- 46.7% vs 49.5% NCT00905307
- 51.6% vs 49.5% NCT00905307
PSP, change
- Aripiprazole (Abilify)
- —Not posted · NCT03485417
- Brexpiprazole (Rexulti)
- 10.5 vs 8.5+2 vs placeboNCT01393613
17 other results
- 13.2 vs 10.3 NCT01396421
- 6.8 vs 5.8 NCT01393613
- 13.1 vs 8.5 NCT01393613
- 12.7 vs 10.3 NCT01396421
- 7.1 vs 5.8 NCT01393613
- 11.7 vs 8.5 NCT01393613
- 7.0 vs 5.8 NCT01393613
- 11.8 vs 10.3 NCT01396421
- 18.6 vs 12.6 NCT01668797
- 15.1 vs 10.3 NCT01668797
- 18.9 vs 17.8 NCT01668797
- 15.2 vs 11.4 NCT01668797
- 13 vs 9.4 NCT01810380
- 4.5 vs 7.6 NCT00905307
- 11.4 vs 7.6 NCT00905307
- 10.7 vs 7.6 NCT00905307
- 12.2 vs 7.6 NCT00905307
Relapse (% of patients)
- Aripiprazole (Abilify)
- 19.4% vs 37.5%−18.1 vs placeboNCT01149655
1 other result
- 10% vs 39.6% NCT00705783
- Brexpiprazole (Rexulti)
- 13.5% vs 38.5%−24.9 vs placeboNCT01668797
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
21 other shared endpoints and safety
Coverage. Aripiprazole (Abilify): 25 of 25 rows · Brexpiprazole (Rexulti): 25 of 25 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aripiprazole (Abilify) Rows use multiple source trials | Brexpiprazole (Rexulti) Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg | -0.52 vs 0.03 placebo kg @ 8wka,b,c,d NCT00345033 · Phase 4 · registry result, not featured evidence | 0.2 vs 0 placebo kg @ 6wka,b,c,d NCT03198078 · Phase 3 |
| CGAS absolute change · score | 0.4 vs -2.08 placebo score @ 6wkb,c NCT01149655 · Phase 3 · registry result, not featured evidence | 10.56 vs 8.08 placebo score @ 6wkb,c NCT03198078 · Phase 3 |
| CGAS absolute change · score No placebo or comparator arm | 5.6 score @ 52wkb,c,e NCT01942148 · Phase 3 · registry result, not featured evidence | 23.05 scoref,b,c,e NCT03238326 · Phase 3 show 3 more doses13.58 score NCT03238326 · Phase 3 14.31 score NCT03238326 · Phase 3 12.92 score NCT03238326 · Phase 3 |
| CGI-I absolute change · score | 2.7 vs 2.5 Brexpiprazole score @ 6wkb,c NCT02054702 · Phase 3 · registry result, not featured evidence | 2.5 vs 2.7 Aripiprazole score @ 6wkb,c NCT02054702 · Phase 3 · registry result, not featured evidence |
| CGI-I absolute value · score | 3.42 vs 3.92 placebo score @ 52wkb,c NCT01149655 · Phase 3 · registry result, not featured evidence | 3.77 vs 4.4 placebo score @ 52wkb,c NCT01668797 · Phase 3 |
| CGI-I absolute value · score No placebo or comparator arm | 3.25 score @ 52wk400/300 mg IM Depotb,c,e NCT00731549 · Phase 3 · registry result, not featured evidence | 1.9 scoref,b,c,e NCT03238326 · Phase 3 show 3 more doses2.1 score NCT03238326 · Phase 3 2.1 score NCT03238326 · Phase 3 2.2 score NCT03238326 · Phase 3 |
| CGI-I absolute change · score No placebo or comparator arm | 2.7 score @ 6.14wk24-30 mg/dayf,g,b,c,h NCT01942161 · Phase 2/3 · registry result, not featured evidence show 2 more doses3.2 score @ 6.14wk6-12 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 3 score @ 6.14wk2 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence | 3.5 score @ 1.57wk4 mgf,g,b,c,h NCT01854944 · Phase 1 · registry result, not featured evidence show 2 more doses2.7 score @ 1.57wk4 mg NCT01854944 · Phase 1 · registry result, not featured evidence 3.8 score @ 1.57wk1 mg NCT01854944 · Phase 1 · registry result, not featured evidence |
| CGI-S absolute change · score No placebo or comparator arm | -0.3 score @ 52wkb,c NCT01942148 · Phase 3 · registry result, not featured evidence 3 other source trials-0.24 score @ 52wk400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence 2.3 score @ 52wk10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 1.1 score @ 52wk5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence | -0.48 score @ 52wkf,b,c NCT01397786 · Phase 3 · registry result, not featured evidence show 2 more doses-0.55 score @ 52wk NCT01397786 · Phase 3 · registry result, not featured evidence -0.97 score @ 52wk NCT01397786 · Phase 3 · registry result, not featured evidence |
| Cognitive Composite Z Score absolute change · Z-score | -0.024 vs 0.045 Brexpiprazole Z-score @ 6wkf,b,c NCT02054702 · Phase 3 · registry result, not featured evidence show 1 more dose0.113 vs -0.01 Brexpiprazole Z-score @ 6wk NCT02054702 · Phase 3 · registry result, not featured evidence | 0.045 vs -0.024 Aripiprazole Z-score @ 6wkf,b,c NCT02054702 · Phase 3 · registry result, not featured evidence show 1 more dose-0.01 vs 0.113 Aripiprazole Z-score @ 6wk NCT02054702 · Phase 3 · registry result, not featured evidence |
| Overall responder rate · % of participants | 48.5% (n=33) vs 60.9% (n=64) Brexpiprazole @ 6wkb,c NCT02054702 · Phase 3 · registry result, not featured evidence | 47.78% (n=180) vs 30.34% (n=178) placebo @ 6wk2 mgf,b,c NCT01396421 · Phase 3 show 2 more doses46.07% (n=178) vs 30.34% (n=178) placebo @ 6wk4 mg NCT01396421 · Phase 3 39.08% (n=87) vs 30.34% (n=178) placebo @ 6wk0.25 mg NCT01396421 · Phase 3 |
| PANSS Negative absolute change · score No placebo or comparator arm | -0.96 score @ 4wk400mgf,i,b,c,j NCT01552772 · Phase 1 · registry result, not featured evidence show 1 more dose-0.92 score @ 4wk400mg NCT01552772 · Phase 1 · registry result, not featured evidence | -2 score @ 52wkf,i,b,c,j NCT01397786 · Phase 3 · registry result, not featured evidence show 2 more doses-2.7 score @ 52wk NCT01397786 · Phase 3 · registry result, not featured evidence -3.7 score @ 52wk NCT01397786 · Phase 3 · registry result, not featured evidence |
| PANSS Negative Subscale absolute change · score | -0.78 vs 0.4 placebo score @ 52wkb,c NCT01149655 · Phase 3 · registry result, not featured evidence | 1.3 vs 0.87 placebo score @ 52wkf,b,c NCT01668797 · Phase 3 show 1 more dose0.39 vs 1.63 placebo score @ 52wk NCT01668797 · Phase 3 |
| PANSS Negative Subscale absolute change · score No placebo or comparator arm | -1.6 score @ 24wkb,c,e NCT01432444 · Phase 3 · registry result, not featured evidence | -4.4 scoref,b,c,e NCT03238326 · Phase 3 show 3 more doses-4.82 score NCT03238326 · Phase 3 -4.89 score NCT03238326 · Phase 3 -4.55 score NCT03238326 · Phase 3 |
| PANSS Positive absolute change · score No placebo or comparator arm | -1.28 score @ 4wk400mgf,i,b,c,j NCT01552772 · Phase 1 · registry result, not featured evidence show 1 more dose-1.25 score @ 4wk400mg NCT01552772 · Phase 1 · registry result, not featured evidence | -2.3 score @ 52wkf,i,b,c,j NCT01397786 · Phase 3 · registry result, not featured evidence show 2 more doses-3.2 score @ 52wk NCT01397786 · Phase 3 · registry result, not featured evidence -5.8 score @ 52wk NCT01397786 · Phase 3 · registry result, not featured evidence |
| PANSS Positive Subscale absolute change · score | 0.16 vs 2.31 placebo score @ 52wkb,c NCT01149655 · Phase 3 · registry result, not featured evidence | -1.21 vs 1.5 placebo score @ 52wkf,b,c NCT01668797 · Phase 3 show 1 more dose0.99 vs 4.17 placebo score @ 52wk NCT01668797 · Phase 3 |
| PANSS Positive Subscale absolute change · score No placebo or comparator arm | -3 score @ 24wkb,c,e NCT01432444 · Phase 3 · registry result, not featured evidence | -5.15 scoref,b,c,e NCT03238326 · Phase 3 show 3 more doses-4.59 score NCT03238326 · Phase 3 -5.2 score NCT03238326 · Phase 3 -5.29 score NCT03238326 · Phase 3 |
| PANSS Total absolute change · score No placebo or comparator arm | -7.9 score @ 52wkb,c,e NCT01942148 · Phase 3 · registry result, not featured evidence 1 other source trial-3.55 score @ 52wk400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence | -19 scoref,b,c,e NCT03238326 · Phase 3 show 3 more doses-18.44 score NCT03238326 · Phase 3 -20.14 score NCT03238326 · Phase 3 -19.76 score NCT03238326 · Phase 3 |
| QLS Total absolute change · score | 7.47 vs 2.8 Paliperidone score @ 28wkk,b,c,l NCT01795547 · Phase 3 · registry result, not featured evidence | 4.049 vs -5.146 Treatment as Usual score @ 12wkk,b,c,l NCT03526354 · Phase 4 · registry result, not featured evidence |
| Remission responder rate · % of participants | 43.8% (n=48) vs 42.1% (n=19) placebo @ 52wkb,c,m NCT01149655 · Phase 3 · registry result, not featured evidence | 29.09% (n=110) vs 23.3% (n=103) placebo @ 6wkb,c,m NCT03198078 · Phase 3 |
| SLOF Total absolute change · score | 6 vs 7.5 Brexpiprazole score @ 6wkb,c NCT02054702 · Phase 3 · registry result, not featured evidence | 7.5 vs 6 Aripiprazole score @ 6wkb,c NCT02054702 · Phase 3 · registry result, not featured evidence |
| Weight absolute change · kg | -1.5 vs 0.3 placebo kg @ 8wka,b,c,d NCT00345033 · Phase 4 · registry result, not featured evidence | 0.8 vs 0 placebo kg @ 6wka,b,c,d NCT03198078 · Phase 3 |
| Dropout rate | 20%n NCT00345033 · Phase 4 · registry result, not featured evidence show 30 more results39.7% NCT01942148 · Phase 3 · registry result, not featured evidence 12.5% NCT01959035 · Phase 3 · registry result, not featured evidence 32.4% NCT01795547 · Phase 3 · registry result, not featured evidence 36.4% NCT02054702 · Phase 3 · registry result, not featured evidence — NCT01149655 · Phase 3 · registry result, not featured evidence — NCT01432444 · Phase 3 · registry result, not featured evidence 20.6%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence 40.2%10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 45%5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —300 or 400 mg NCT00706654 · Phase 3 · registry result, not featured evidence —25 or 50 mg NCT00706654 · Phase 3 · registry result, not featured evidence 84.7% NCT01001702 · Phase 3 · registry result, not featured evidence —Aripiprazole Depot NCT00705783 · Phase 3 · registry result, not featured evidence —Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · registry result, not featured evidence 37.8% NCT00216476 · Phase 3 · registry result, not featured evidence 26.8% NCT00102518 · Phase 3 · registry result, not featured evidence 16%10 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 17.6%30 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 14.6%24-30 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 20%6-12 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 22.9%2 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 11.1%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 26.3%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 6.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence 0%30 mg NCT00102479 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00102479 · Phase 1 · registry result, not featured evidence 0%20 mg NCT00102479 · Phase 1 · registry result, not featured evidence 16.7% NCT01338298 · Phase na · registry result, not featured evidence | 30.6%2 mgn NCT01393613 · Phase 3 show 45 more results29.3%4 mg NCT01393613 · Phase 3 32.5%1 mg NCT01393613 · Phase 3 —2 mg NCT01396421 · Phase 3 31.9%2 mg NCT01396421 · Phase 3 32.8%4 mg NCT01396421 · Phase 3 —4 mg NCT01396421 · Phase 3 —0.25 mg NCT01396421 · Phase 3 37.8%0.25 mg NCT01396421 · Phase 3 0%De Novo (Conversion Period) NCT03238326 · Phase 3 —De Novo (OLT Period) NCT03238326 · Phase 3 —Prior & Current Brexpiprazole (OLT NCT03238326 · Phase 3 —Prior Aripiprazole & Current Brexp NCT03238326 · Phase 3 —Prior Placebo & Current Brexpipraz NCT03238326 · Phase 3 —Prior and Current Brexpiprazole NCT03238326 · Phase 3 2.7% NCT03198078 · Phase 3 — NCT01668797 · Phase 3 28.6% NCT03526354 · Phase 4 · registry result, not featured evidence 15.8%2 mg NCT02194933 · Phase 3 · registry result, not featured evidence 47.4%4 mg NCT02194933 · Phase 3 · registry result, not featured evidence 12.3%De Novo NCT01397786 · Phase 3 · registry result, not featured evidence —De Novo (Phase A) NCT01397786 · Phase 3 · registry result, not featured evidence —De Novo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence 0%Prior Brexpiprazole NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Brexpiprazole (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Placebo NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Placebo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence 51.9% NCT01810783 · Phase 3 · registry result, not featured evidence 25.2% NCT01810380 · Phase 3 · registry result, not featured evidence 49% NCT02013622 · Phase 3 · registry result, not featured evidence 37.5% NCT02054702 · Phase 3 · registry result, not featured evidence 29.6%2 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 39.8%4 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 37.4%1 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 52.4%0.25 mg NCT00905307 · Phase 2 · registry result, not featured evidence —High-dose NCT00905307 · Phase 2 · registry result, not featured evidence 41.6%Low-dose NCT00905307 · Phase 2 · registry result, not featured evidence 41.1%Mid-dose NCT00905307 · Phase 2 · registry result, not featured evidence —Fasted Stated NCT06036108 · Phase 1 · registry result, not featured evidence —Fed Stated NCT06036108 · Phase 1 · registry result, not featured evidence 0%4 mg NCT01854944 · Phase 1 · registry result, not featured evidence 25%4 mg NCT01854944 · Phase 1 · registry result, not featured evidence 0%1 mg NCT01854944 · Phase 1 · registry result, not featured evidence 14.9%4 mg NCT01423916 · Phase 1 · registry result, not featured evidence 27.4%12 mg NCT01423916 · Phase 1 · registry result, not featured evidence —3mg NCT01289080 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —n NCT00345033 · Phase 4 · registry result, not featured evidence show 30 more results5.9% NCT01942148 · Phase 3 · registry result, not featured evidence 5.7% NCT01959035 · Phase 3 · registry result, not featured evidence 10.8% NCT01795547 · Phase 3 · registry result, not featured evidence 3% NCT02054702 · Phase 3 · registry result, not featured evidence — NCT01149655 · Phase 3 · registry result, not featured evidence — NCT01432444 · Phase 3 · registry result, not featured evidence 2.9%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence 6.2%10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 0%5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —300 or 400 mg NCT00706654 · Phase 3 · registry result, not featured evidence —25 or 50 mg NCT00706654 · Phase 3 · registry result, not featured evidence 8.2% NCT01001702 · Phase 3 · registry result, not featured evidence —Aripiprazole Depot NCT00705783 · Phase 3 · registry result, not featured evidence —Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · registry result, not featured evidence 2.2% NCT00216476 · Phase 3 · registry result, not featured evidence — NCT00102518 · Phase 3 · registry result, not featured evidence 7%10 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 3.9%30 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 12.2%24-30 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 6.7%6-12 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 2.9%2 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence —400 mg NCT01646827 · Phase 1 · registry result, not featured evidence —400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 1.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence —30 mg NCT00102479 · Phase 1 · registry result, not featured evidence —25 mg NCT00102479 · Phase 1 · registry result, not featured evidence —20 mg NCT00102479 · Phase 1 · registry result, not featured evidence — NCT01338298 · Phase na · registry result, not featured evidence | 5.9%2 mgn NCT01393613 · Phase 3 show 45 more results7.1%4 mg NCT01393613 · Phase 3 9.2%1 mg NCT01393613 · Phase 3 —2 mg NCT01396421 · Phase 3 8.2%2 mg NCT01396421 · Phase 3 9.4%4 mg NCT01396421 · Phase 3 —4 mg NCT01396421 · Phase 3 —0.25 mg NCT01396421 · Phase 3 13.3%0.25 mg NCT01396421 · Phase 3 —De Novo (Conversion Period) NCT03238326 · Phase 3 —De Novo (OLT Period) NCT03238326 · Phase 3 —Prior & Current Brexpiprazole (OLT NCT03238326 · Phase 3 —Prior Aripiprazole & Current Brexp NCT03238326 · Phase 3 —Prior Placebo & Current Brexpipraz NCT03238326 · Phase 3 —Prior and Current Brexpiprazole NCT03238326 · Phase 3 0% NCT03198078 · Phase 3 — NCT01668797 · Phase 3 — NCT03526354 · Phase 4 · registry result, not featured evidence —2 mg NCT02194933 · Phase 3 · registry result, not featured evidence —4 mg NCT02194933 · Phase 3 · registry result, not featured evidence 3.5%De Novo NCT01397786 · Phase 3 · registry result, not featured evidence —De Novo (Phase A) NCT01397786 · Phase 3 · registry result, not featured evidence —De Novo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence 0%Prior Brexpiprazole NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Brexpiprazole (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Placebo NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Placebo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence 15.2% NCT01810783 · Phase 3 · registry result, not featured evidence 9.3% NCT01810380 · Phase 3 · registry result, not featured evidence 6.1% NCT02013622 · Phase 3 · registry result, not featured evidence 4.7% NCT02054702 · Phase 3 · registry result, not featured evidence 10.4%2 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 15.9%4 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 16.5%1 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 7.1%0.25 mg NCT00905307 · Phase 2 · registry result, not featured evidence —High-dose NCT00905307 · Phase 2 · registry result, not featured evidence 4.5%Low-dose NCT00905307 · Phase 2 · registry result, not featured evidence 5.6%Mid-dose NCT00905307 · Phase 2 · registry result, not featured evidence —Fasted Stated NCT06036108 · Phase 1 · registry result, not featured evidence —Fed Stated NCT06036108 · Phase 1 · registry result, not featured evidence —4 mg NCT01854944 · Phase 1 · registry result, not featured evidence —4 mg NCT01854944 · Phase 1 · registry result, not featured evidence —1 mg NCT01854944 · Phase 1 · registry result, not featured evidence 6.8%4 mg NCT01423916 · Phase 1 · registry result, not featured evidence 12.3%12 mg NCT01423916 · Phase 1 · registry result, not featured evidence —3mg NCT01289080 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 0%n NCT00345033 · Phase 4 · registry result, not featured evidence show 30 more results10.3% NCT01942148 · Phase 3 · registry result, not featured evidence 3.4% NCT01959035 · Phase 3 · registry result, not featured evidence 8.3% NCT01795547 · Phase 3 · registry result, not featured evidence 3% NCT02054702 · Phase 3 · registry result, not featured evidence 3.1% NCT01149655 · Phase 3 · registry result, not featured evidence 14.2% NCT01432444 · Phase 3 · registry result, not featured evidence 8.8%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence —10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 0%5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 13.4%10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 5.7%300 or 400 mg NCT00706654 · Phase 3 · registry result, not featured evidence 8.4%25 or 50 mg NCT00706654 · Phase 3 · registry result, not featured evidence 12.9% NCT01001702 · Phase 3 · registry result, not featured evidence —Aripiprazole Depot NCT00705783 · Phase 3 · registry result, not featured evidence 4.1%Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · registry result, not featured evidence 15.6% NCT00216476 · Phase 3 · registry result, not featured evidence 6.2% NCT00102518 · Phase 3 · registry result, not featured evidence 4%10 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 3.9%30 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 4.9%24-30 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 6.7%6-12 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 0%2 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 0%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 0%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 1.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence 0%30 mg NCT00102479 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00102479 · Phase 1 · registry result, not featured evidence 0%20 mg NCT00102479 · Phase 1 · registry result, not featured evidence 0% NCT01338298 · Phase na · registry result, not featured evidence | 2.2%2 mgn NCT01393613 · Phase 3 show 45 more results2.2%4 mg NCT01393613 · Phase 3 2.5%1 mg NCT01393613 · Phase 3 2.2%2 mg NCT01396421 · Phase 3 —2 mg NCT01396421 · Phase 3 —4 mg NCT01396421 · Phase 3 1.1%4 mg NCT01396421 · Phase 3 4.4%0.25 mg NCT01396421 · Phase 3 —0.25 mg NCT01396421 · Phase 3 0%De Novo (Conversion Period) NCT03238326 · Phase 3 5%De Novo (OLT Period) NCT03238326 · Phase 3 —Prior & Current Brexpiprazole (OLT NCT03238326 · Phase 3 1.1%Prior Aripiprazole & Current Brexp NCT03238326 · Phase 3 3.4%Prior Placebo & Current Brexpipraz NCT03238326 · Phase 3 4.1%Prior and Current Brexpiprazole NCT03238326 · Phase 3 0.9% NCT03198078 · Phase 3 3.1% NCT01668797 · Phase 3 0% NCT03526354 · Phase 4 · registry result, not featured evidence 0%2 mg NCT02194933 · Phase 3 · registry result, not featured evidence 0%4 mg NCT02194933 · Phase 3 · registry result, not featured evidence —De Novo NCT01397786 · Phase 3 · registry result, not featured evidence 1.8%De Novo (Phase A) NCT01397786 · Phase 3 · registry result, not featured evidence 11.2%De Novo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Brexpiprazole NCT01397786 · Phase 3 · registry result, not featured evidence 14.9%Prior Brexpiprazole (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence —Prior Placebo NCT01397786 · Phase 3 · registry result, not featured evidence 8.9%Prior Placebo (Phase B) NCT01397786 · Phase 3 · registry result, not featured evidence 14.8% NCT01810783 · Phase 3 · registry result, not featured evidence 4.7% NCT01810380 · Phase 3 · registry result, not featured evidence 0% NCT02013622 · Phase 3 · registry result, not featured evidence 4.7% NCT02054702 · Phase 3 · registry result, not featured evidence 4.4%2 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 4.4%4 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 7%1 mg NCT01451164 · Phase 2/3 · registry result, not featured evidence 0%0.25 mg NCT00905307 · Phase 2 · registry result, not featured evidence 4.3%High-dose NCT00905307 · Phase 2 · registry result, not featured evidence 3.4%Low-dose NCT00905307 · Phase 2 · registry result, not featured evidence 5.6%Mid-dose NCT00905307 · Phase 2 · registry result, not featured evidence 0%Fasted Stated NCT06036108 · Phase 1 · registry result, not featured evidence 1.8%Fed Stated NCT06036108 · Phase 1 · registry result, not featured evidence 0%4 mg NCT01854944 · Phase 1 · registry result, not featured evidence 0%4 mg NCT01854944 · Phase 1 · registry result, not featured evidence 0%1 mg NCT01854944 · Phase 1 · registry result, not featured evidence 1.4%4 mg NCT01423916 · Phase 1 · registry result, not featured evidence 0%12 mg NCT01423916 · Phase 1 · registry result, not featured evidence 0%3mg NCT01289080 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | n eye irritation/swelling 6.3% (placebo 0%) psychiatric decompensation 6.3% (placebo 0%) psychiatric decompensation 6.3% (placebo 0%) NCT00345033 · Phase 4 · registry result, not featured evidence show 27 more resultsnasopharyngitis 45.6% somnolence 20.6% nausea 17.6% NCT01942148 · Phase 3 · registry result, not featured evidence weight increased 6.8% NCT01959035 · Phase 3 · registry result, not featured evidence accidental overdose 20.8% insomnia 11.8% weight increased 9% NCT01795547 · Phase 3 · registry result, not featured evidence akathisia 21.2% headache 12.1% constipation 9.1% NCT02054702 · Phase 3 · registry result, not featured evidence schizophrenia 9.2% (placebo 16.7%) weight increased 8.2% (placebo 10.4%) nasopharyngitis 7.1% (placebo 2.1%) NCT01149655 · Phase 3 · registry result, not featured evidence insomnia 6.7% akathisia 6.3% weight increased 2.3% NCT01432444 · Phase 3 · registry result, not featured evidence 400/300 mg IM Depot headache 7.6% nasopharyngitis 7% anxiety 6.8% NCT00731549 · Phase 3 · registry result, not featured evidence 5 - 30 mg QD pyrexia 35% headache 30% cough 15% NCT00239356 · Phase 3 · registry result, not featured evidence 10 - 30 mg QD back pain 7.2% anxiety 6.2% headache 6.2% NCT00239356 · Phase 3 · registry result, not featured evidence 300 or 400 mg insomnia 11.7% akathisia 10.6% headache 9.8% NCT00706654 · Phase 3 · registry result, not featured evidence 25 or 50 mg insomnia 13.7% back pain 11.5% weight decreased 9.2% NCT00706654 · Phase 3 · registry result, not featured evidence headache 15.3% influenza 10.6% weight increased 10.6% NCT01001702 · Phase 3 · registry result, not featured evidence insomnia 10% (placebo 9%) weight increased 9.7% (placebo 9.7%) anxiety 5.9% (placebo 7.5%) NCT00705783 · Phase 3 · registry result, not featured evidence insomnia 24.4% anxiety 15.6% headache 11.1% NCT00216476 · Phase 3 · registry result, not featured evidence extrapyramidal disorder 14.8% somnolence 12.9% headache 9.5% NCT00102518 · Phase 3 · registry result, not featured evidence 10 mg/day headache 16% (placebo 10%) extrapyramidal disorder 13% (placebo 5%) insomnia 11% (placebo 15%) NCT00102063 · Phase 3 · registry result, not featured evidence 30 mg/day extrapyramidal disorder 21.6% (placebo 5%) somnolence 21.6% (placebo 6%) tremor 11.8% (placebo 2%) NCT00102063 · Phase 3 · registry result, not featured evidence 24-30 mg/day nausea 22% insomnia 17.1% salivary hypersecretion 14.6% NCT01942161 · Phase 2/3 · registry result, not featured evidence 6-12 mg/day insomnia 20% somnolence 20% epistaxis 13.3% NCT01942161 · Phase 2/3 · registry result, not featured evidence 2 mg/day nausea 20% insomnia 14.3% nasopharyngitis 14.3% NCT01942161 · Phase 2/3 · registry result, not featured evidence 400 mg injection site pain 35.3% headache 23.5% akathisia 17.6% NCT01646827 · Phase 1 · registry result, not featured evidence 400 mg injection site pain 27.8% headache 22.2% akathisia 16.7% NCT01646827 · Phase 1 · registry result, not featured evidence 400mg injection site pain 6.7% toothache 6.7% blood creatine phosphokinase increased 5% NCT01552772 · Phase 1 · registry result, not featured evidence 30 mg headache 50% sedation 33.3% abdominal pain upper 16.7% NCT00102479 · Phase 1 · registry result, not featured evidence 25 mg abdominal pain upper 42.9% acne 28.6% dizziness 28.6% NCT00102479 · Phase 1 · registry result, not featured evidence 20 mg headache 50% insomnia 25% musculoskeletal stiffness 25% NCT00102479 · Phase 1 · registry result, not featured evidence nausea 50% (placebo 22.2%) vomiting 50% (placebo 38.9%) diarrhea 45% (placebo 38.9%) NCT01338298 · Phase na · registry result, not featured evidence | 2 mgn insomnia 13.4% (placebo 14.7%) headache 10.8% (placebo 14.7%) agitation 8.6% (placebo 7.1%) NCT01393613 · Phase 3 show 38 more results4 mg insomnia 15.2% (placebo 14.7%) headache 10.3% (placebo 14.7%) agitation 7.1% (placebo 7.1%) NCT01393613 · Phase 3 1 mg insomnia 12.5% (placebo 14.7%) agitation 8.3% (placebo 7.1%) headache 7.5% (placebo 14.7%) NCT01393613 · Phase 3 2 mg headache 9.3% (placebo 8.2%) insomnia 8.8% (placebo 9.8%) agitation 6% (placebo 10.3%) NCT01396421 · Phase 3 4 mg headache 12.2% (placebo 8.2%) insomnia 8.3% (placebo 9.8%) agitation 7.2% (placebo 10.3%) NCT01396421 · Phase 3 0.25 mg headache 10% (placebo 8.2%) insomnia 8.9% (placebo 9.8%) schizophrenia 6.7% (placebo 9.8%) NCT01396421 · Phase 3 headache 6.4% (placebo 4.8%) nausea 6.4% (placebo 3.8%) somnolence 4.5% (placebo 4.8%) NCT03198078 · Phase 3 fatigure/tiredness 14.3% nausea 14.3% cold-like symptoms 9.5% NCT03526354 · Phase 4 · registry result, not featured evidence 2 mg headache 15.8% insomnia 10.5% irritability 10.5% NCT02194933 · Phase 3 · registry result, not featured evidence 4 mg agitation 10.5% anxiety 10.5% back pain 10.5% NCT02194933 · Phase 3 · registry result, not featured evidence insomnia 12.5% headache 9.4% agitation 9% NCT01397786 · Phase 3 · registry result, not featured evidence insomnia 8.4% weight increased 7.8% headache 6.9% NCT01397786 · Phase 3 · registry result, not featured evidence insomnia 8.4% weight increased 7.4% akathisia 6.9% NCT01397786 · Phase 3 · registry result, not featured evidence weight increased 10.5% headache 8.6% insomnia 8.1% NCT01810783 · Phase 3 · registry result, not featured evidence insomnia 8.7% (placebo 6.2%) akathisia 6% (placebo 2.5%) headache 5.3% (placebo 6.8%) NCT01810380 · Phase 3 · registry result, not featured evidence insomnia 14.3% somnolence 8.2% nausea 6.1% NCT02013622 · Phase 3 · registry result, not featured evidence akathisia 9.4% weight increased 9.4% dry mouth 7.8% NCT02054702 · Phase 3 · registry result, not featured evidence 2 mg schizophrenia 11.4% (placebo 24.1%) headache 7.9% (placebo 4.3%) constipation 7% (placebo 7.8%) NCT01451164 · Phase 2/3 · registry result, not featured evidence 4 mg schizophrenia 20.4% (placebo 24.1%) nasopharyngitis 8.8% (placebo 9.5%) vomiting 7.1% (placebo 3.4%) NCT01451164 · Phase 2/3 · registry result, not featured evidence 1 mg schizophrenia 17.4% (placebo 24.1%) nasopharyngitis 10.4% (placebo 9.5%) constipation 7% (placebo 7.8%) NCT01451164 · Phase 2/3 · registry result, not featured evidence 0.25 mg headache 14.3% (placebo 10.5%) anxiety 11.9% (placebo 10.5%) agitation 9.5% (placebo 4.2%) NCT00905307 · Phase 2 · registry result, not featured evidence High-dose akathisia 15.1% (placebo 4.2%) anxiety 10.8% (placebo 10.5%) insomnia 9.7% (placebo 16.8%) NCT00905307 · Phase 2 · registry result, not featured evidence Low-dose insomnia 13.5% (placebo 16.8%) headache 9% (placebo 10.5%) anxiety 7.9% (placebo 10.5%) NCT00905307 · Phase 2 · registry result, not featured evidence Mid-dose headache 14.4% (placebo 10.5%) insomnia 10% (placebo 16.8%) weight increased 10% (placebo 3.2%) NCT00905307 · Phase 2 · registry result, not featured evidence nausea 9.6% somnolence 9.6% diarrhoea 5.8% NCT06036108 · Phase 1 · registry result, not featured evidence vomiting 20% nausea 12.7% somnolence 12.7% NCT06036108 · Phase 1 · registry result, not featured evidence 4 mg abdominal pain 25% akathisia 25% blepharospasm 25% NCT01854944 · Phase 1 · registry result, not featured evidence 4 mg akathisia 25% dental carries 25% dyspepsia 25% NCT01854944 · Phase 1 · registry result, not featured evidence 1 mg abdominal discomfort 50% agitation 25% abdominal pain 0% NCT01854944 · Phase 1 · registry result, not featured evidence 4 mg nausea 10% (placebo 5.9%) application site dermatitis 8.6% (placebo 5.9%) dizziness 8.6% (placebo 1.5%) NCT01423916 · Phase 1 · registry result, not featured evidence 12 mg dizziness 11.9% (placebo 1.5%) akathisia 7.5% (placebo 1.5%) extrapyramidal disorder 7.5% (placebo 1.5%) NCT01423916 · Phase 1 · registry result, not featured evidence 3mg somnolence 15.8% headache 10.5% orthostatic hypotension 10.5% NCT01289080 · Phase 1 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 4.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 6 weeks versus 8 weeks.
- eThe assessment timepoint is not available for both results.
- fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- gTrial phases differ: Phase 1 versus Phase 2/3.
- hAssessment timepoints differ: 1.57 weeks versus 6.14 weeks.
- iTrial phases differ: Phase 3 versus Phase 1.
- jAssessment timepoints differ: 52 weeks versus 4 weeks.
- kTrial phases differ: Phase 4 versus Phase 3.
- lAssessment timepoints differ: 12 weeks versus 28 weeks.
- mAssessment timepoints differ: 6 weeks versus 52 weeks.
- nPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aripiprazole (Abilify)
show 1 more result
show 1 more result
show 27 more results
show 14 more results
+ 30 further endpoints in the CSV export.
Brexpiprazole (Rexulti)
show 17 more results
show 35 more results
show 35 more results
show 8 more results
show 31 more results
show 31 more results
show 31 more results
show 28 more results
show 31 more results
show 31 more results
show 2 more results
show 3 more results
+ 36 further endpoints in the CSV export.
Major Depressive Disorder
Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Major Depressive Disorder pipeline
Aripiprazole (Abilify)
Marketed by Otsuka Holdings and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07011693 (registry estimate)
No aligned efficacy figure on record for this race.
Brexpiprazole (Rexulti)
Marketed by Otsuka Holdings and partners
NCT01360632 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled Phase 3 trial with 677 randomized participants and a clinical primary endpoint (MADRS change). The 3 mg brexpiprazole arm met the primary endpoint versus placebo (p=0.0327), while the 1 mg arm missed (p=0.0925). Because the primary result was not consistent across the two active doses, the evidence is considered moderate rather than strong.
Next expected readout: December 2028 · NCT05017311 (registry estimate)
Reported efficacy
Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample. (Baseline and Week 14); Change From Baseline (End of Phase A [Week 8]) to Week 14 in MADRS Total Score for the Efficacy Sample Per the Final Protocol. (Baseline and Week 14): Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample. (Baseline and Week 14): Brexpiprazole 2 mg/Day + ADT -8.27 Units on a scale (Standard Error 0.61) vs Double-blind Placebo + ADT -5.15 Units on a scale (Standard Error 0.6) (met)
Result source: NCT01360645
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aripiprazole (Abilify) | Brexpiprazole (Rexulti) |
|---|---|---|
| MADRS, change (acute) | —Not posted · NCT00095823 | -8.3 vs -5.2−3.1 vs placeboNCT0136064568 other results
|
| CGI-S, change (acute) | —Not posted · NCT00095823 | -0.9 vs -0.6−0.3 vs placeboNCT0136064560 other results
|
| MADRS response | —Not posted · NCT00095823 | 23.5% vs 14.7%+8.8 vs placeboNCT0136064551 other results
|
| MADRS remission | —Not posted · NCT00095823 | 14.4% vs 8.4%+6 vs placeboNCT0136064550 other results
|
| Relapse (% of patients) | —Not posted · NCT00095823 | 22.5% vs 20.6%+1.9 vs placeboNCT03538691 |
MADRS, change (acute)
- Aripiprazole (Abilify)
- —Not posted · NCT00095823
- Brexpiprazole (Rexulti)
- -8.3 vs -5.2−3.1 vs placeboNCT01360645
68 other results
- -8.4 vs -5.2 NCT01360645
- -8.2 vs -6.7 NCT03697603
- -7.7 vs -6.5 NCT01360632
- -7.6 vs 6.3 NCT01360632
- -8.5 vs -6.7 NCT03697603
- -8.0 vs -6.5 NCT01360632
- -8.3 vs 6.3 NCT01360632
- -10.4 vs -8.1 NCT02196506
- -8.3 vs -5.1 NCT01360645
- -8.3 vs -5.0 NCT01360645
- -7.2 vs -4.6 NCT01360645
- -7.2 vs -4.7 NCT01360645
- -6.7 vs -4.1 NCT01360645
- -6.6 vs -4.2 NCT01360645
- -5.2 vs -3.4 NCT01360645
- -5.0 vs -3.5 NCT01360645
- -3.1 vs -1.9 NCT01360645
- -3.0 vs -1.7 NCT01360645
- -7.5 vs -6.0 NCT01360632
- -7.6 vs -5.9 NCT01360632
- -7.1 vs -5.5 NCT01360632
- -7.1 vs -5.5 NCT01360632
- -6.3 vs -4.8 NCT01360632
- -6.2 vs -4.9 NCT01360632
- -5.3 vs -3.9 NCT01360632
- -5.1 vs -4.0 NCT01360632
- -3.3 vs -2.2 NCT01360632
- -3.1 vs -2.2 NCT01360632
- -7.7 vs -6.0 NCT01360632
- -8.1 vs -5.9 NCT01360632
- -6.8 vs -5.5 NCT01360632
- -7.1 vs -5.5 NCT01360632
- -5.6 vs -4.8 NCT01360632
- -5.8 vs -4.9 NCT01360632
- -4.8 vs -3.9 NCT01360632
- -4.9 vs -4.0 NCT01360632
- -2.5 vs -2.2 NCT01360632
- -2.6 vs -2.2 NCT01360632
- -11.1 vs -8.9 NCT02196506
- -6.3 vs -5.9 NCT01838681
- -11.8 vs -8.9 NCT02196506
- -4.4 vs -3.2 NCT01727726
- -2.6 vs -1.0 NCT01727726
- -8.2 vs -6.1 NCT00797966
- -6.5 vs -6.1 NCT00797966
- -6.6 vs -6.1 NCT00797966
- -8.2 vs -7.0 NCT01052077
- -7.2 vs -5.5 NCT00797966
- -7.0 vs -4.4 NCT00797966
- -5.9 vs -4.4 NCT00797966
- -5.0 vs -3.6 NCT00797966
- -2.8 vs -2.5 NCT00797966
- -6.8 vs -5.5 NCT00797966
- -6.3 vs -4.4 NCT00797966
- -5.7 vs -4.4 NCT00797966
- -3.8 vs -3.6 NCT00797966
- -3 vs -2.5 NCT00797966
- -6.9 vs -5.5 NCT00797966
- -7.0 vs -4.4 NCT00797966
- -5.5 vs -4.4 NCT00797966
- -3.7 vs -3.6 NCT00797966
- -2.1 vs -2.5 NCT00797966
- -8.2 vs -7.0 NCT01052077
- -9 vs -7.2 NCT01052077
- -8.4 vs -6.2 NCT01052077
- -7.2 vs -5.2 NCT01052077
- -5.9 vs -4.0 NCT01052077
- -3.3 vs -2.0 NCT01052077
CGI-S, change (acute)
- Aripiprazole (Abilify)
- —Not posted · NCT00095823
- Brexpiprazole (Rexulti)
- -0.9 vs -0.6−0.3 vs placeboNCT01360645
60 other results
- -0.9 vs -0.6 NCT01360645
- -0.9 vs -0.5 NCT01360645
- -0.8 vs -0.5 NCT01360645
- -0.7 vs -0.5 NCT01360645
- -0.7 vs -0.5 NCT01360645
- -0.6 vs -0.4 NCT01360645
- -0.6 vs -0.4 NCT01360645
- -0.5 vs -0.3 NCT01360645
- -0.4 vs -0.3 NCT01360645
- -0.3 vs -0.1 NCT01360645
- -0.2 vs -0.1 NCT01360645
- -0.9 vs -0.8 NCT01360632
- -0.9 vs -0.7 NCT01360632
- -0.8 vs -0.7 NCT01360632
- -0.8 vs -0.6 NCT01360632
- -0.7 vs -0.6 NCT01360632
- -0.7 vs -0.6 NCT01360632
- -0.6 vs -0.4 NCT01360632
- -0.6 vs -0.5 NCT01360632
- -0.5 vs -0.3 NCT01360632
- -0.5 vs -0.3 NCT01360632
- -0.3 vs -0.2 NCT01360632
- -0.2 vs -0.2 NCT01360632
- -0.9 vs -0.8 NCT01360632
- -0.9 vs -0.7 NCT01360632
- -0.8 vs -0.7 NCT01360632
- -0.8 vs -0.6 NCT01360632
- -0.7 vs -0.6 NCT01360632
- -0.7 vs -0.6 NCT01360632
- -0.5 vs -0.4 NCT01360632
- -0.5 vs -0.5 NCT01360632
- -0.5 vs -0.3 NCT01360632
- -0.5 vs -0.3 NCT01360632
- -0.2 vs -0.2 NCT01360632
- -0.2 vs -0.2 NCT01360632
- -0.8 vs -0.8 NCT01838681
- -1.1 vs -0.7 NCT00797966
- -0.9 vs -0.6 NCT00797966
- -0.9 vs -0.5 NCT00797966
- -0.7 vs -0.5 NCT00797966
- -0.6 vs -0.4 NCT00797966
- -0.3 vs -0.2 NCT00797966
- -0.8 vs -0.7 NCT00797966
- -0.8 vs -0.6 NCT00797966
- -0.7 vs -0.5 NCT00797966
- -0.5 vs -0.5 NCT00797966
- -0.4 vs -0.4 NCT00797966
- -0.3 vs -0.2 NCT00797966
- -0.8 vs -0.7 NCT00797966
- -0.7 vs -0.6 NCT00797966
- -0.8 vs -0.5 NCT00797966
- -0.5 vs -0.5 NCT00797966
- -0.4 vs -0.4 NCT00797966
- -0.2 vs -0.2 NCT00797966
- -0.9 vs -0.8 NCT01052077
- -1 vs -0.8 NCT01052077
- -0.9 vs -0.7 NCT01052077
- -0.8 vs -0.6 NCT01052077
- -0.6 vs -0.4 NCT01052077
- -0.3 vs -0.2 NCT01052077
MADRS response
- Aripiprazole (Abilify)
- —Not posted · NCT00095823
- Brexpiprazole (Rexulti)
- 23.5% vs 14.7%+8.8 vs placeboNCT01360645
51 other results
- 23.4% vs 15.7% NCT01360645
- 23.1% vs 15.1% NCT01360632
- 23.2% vs 14.3% NCT01360632
- 18.2% vs 15.6% NCT01360632
- 18% vs 14.3% NCT01360632
- 16.9% vs 10.1% NCT01360632
- 16.6% vs 10.3% NCT01360632
- 13.3% vs 8.7% NCT01360632
- 13.3% vs 8.4% NCT01360632
- 10.2% vs 5.0% NCT01360632
- 7.6% vs 4.9% NCT01360632
- 4.5% vs 2.8% NCT01360632
- 3.4% vs 3.0% NCT01360632
- 22.1% vs 15.1% NCT01360632
- 23% vs 14.3% NCT01360632
- 18.6% vs 15.6% NCT01360632
- 19.2% vs 14.3% NCT01360632
- 15.5% vs 10.1% NCT01360632
- 16.4% vs 10.3% NCT01360632
- 10.6% vs 8.7% NCT01360632
- 11.3% vs 8.4% NCT01360632
- 6.2% vs 5.0% NCT01360632
- 6.1% vs 4.9% NCT01360632
- 0.5% vs 2.8% NCT01360632
- 0.5% vs 3.0% NCT01360632
- 10.5% vs 6.8% NCT01727726
- 18.6% vs 17.3% NCT01838681
- 34.7% vs 19.8% NCT00797966
- 25.4% vs 18.3% NCT00797966
- 25.4% vs 11.9% NCT00797966
- 18.6% vs 13.5% NCT00797966
- 11% vs 9.5% NCT00797966
- 2.6% vs 8.3% NCT00797966
- 20.2% vs 19.8% NCT00797966
- 22.7% vs 18.3% NCT00797966
- 15.1% vs 11.9% NCT00797966
- 15.1% vs 13.5% NCT00797966
- 8.4% vs 9.5% NCT00797966
- 6.8% vs 8.3% NCT00797966
- 27.4% vs 19.8% NCT00797966
- 24.2% vs 18.3% NCT00797966
- 30.6% vs 11.9% NCT00797966
- 19.4% vs 13.5% NCT00797966
- 8.1% vs 9.5% NCT00797966
- 4.9% vs 8.3% NCT00797966
- 29.9% vs 19.9% NCT01052077
- 29.9% vs 18.2% NCT01052077
- 30.4% vs 15.5% NCT01052077
- 22.3% vs 14.4% NCT01052077
- 15.8% vs 8.8% NCT01052077
- 6% vs 2.2% NCT01052077
MADRS remission
- Aripiprazole (Abilify)
- —Not posted · NCT00095823
- Brexpiprazole (Rexulti)
- 14.4% vs 8.4%+6 vs placeboNCT01360645
50 other results
- 14.9% vs 9.0% NCT01360645
- 15.1% vs 11.9% NCT01360632
- 14.7% vs 10.8% NCT01360632
- 10.7% vs 9.2% NCT01360632
- 9.9% vs 8.4% NCT01360632
- 11.1% vs 6.0% NCT01360632
- 10.4% vs 6.4% NCT01360632
- 8.4% vs 5.5% NCT01360632
- 8.1% vs 5.4% NCT01360632
- 4% vs 4.1% NCT01360632
- 2.4% vs 3.9% NCT01360632
- 3.1% vs 2.8% NCT01360632
- 1.9% vs 3.0% NCT01360632
- 13.7% vs 11.9% NCT01360632
- 14.1% vs 10.8% NCT01360632
- 12.8% vs 9.2% NCT01360632
- 13.1% vs 8.4% NCT01360632
- 8.8% vs 6.0% NCT01360632
- 9.4% vs 6.4% NCT01360632
- 6.2% vs 5.5% NCT01360632
- 6.6% vs 5.4% NCT01360632
- 2.6% vs 4.1% NCT01360632
- 2.8% vs 3.9% NCT01360632
- 0.5% vs 2.8% NCT01360632
- 0.5% vs 3.0% NCT01360632
- 12% vs 10.5% NCT01838681
- 23.7% vs 13.5% NCT00797966
- 15.3% vs 15.1% NCT00797966
- 19.5% vs 10.3% NCT00797966
- 14.4% vs 11.1% NCT00797966
- 10.2% vs 8.7% NCT00797966
- 1.7% vs 4.1% NCT00797966
- 15.1% vs 13.5% NCT00797966
- 16.8% vs 15.1% NCT00797966
- 10.1% vs 10.3% NCT00797966
- 10.1% vs 11.1% NCT00797966
- 5.0% vs 8.7% NCT00797966
- 1.7% vs 4.1% NCT00797966
- 22.6% vs 13.5% NCT00797966
- 19.4% vs 15.1% NCT00797966
- 21% vs 10.3% NCT00797966
- 12.9% vs 11.1% NCT00797966
- 8.1% vs 8.7% NCT00797966
- 3.3% vs 4.1% NCT00797966
- 26.1% vs 14.9% NCT01052077
- 25% vs 13.8% NCT01052077
- 22.8% vs 10.5% NCT01052077
- 16.8% vs 9.9% NCT01052077
- 8.2% vs 3.9% NCT01052077
- 3.8% vs 1.7% NCT01052077
Relapse (% of patients)
- Aripiprazole (Abilify)
- —Not posted · NCT00095823
- Brexpiprazole (Rexulti)
- 22.5% vs 20.6%+1.9 vs placeboNCT03538691
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Aripiprazole (Abilify): registry results are on file for Major Depressive Disorder, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Aripiprazole (Abilify): 0 of 4 rows · Brexpiprazole (Rexulti): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Brexpiprazole (Rexulti) |
|---|---|
| Dropout rate | —1 mga NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3 show 32 more results—1 mg NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3 —3 mg NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3 —3 mg NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3 —2 mg/Day NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3 9% NCT04830215 · Phase 4 · registry result, not featured evidence —Brexpiprazole NCT03149991 · Phase 4 · registry result, not featured evidence 16%Ketamine/Brexpiprazole Arm NCT03149991 · Phase 4 · registry result, not featured evidence · combination 33.3%Phase A: Brexpiprazole + ADT NCT03538691 · Phase 3 · registry result, not featured evidence · combination —Phase B: Brexpiprazole + ADT NCT03538691 · Phase 3 · registry result, not featured evidence · combination —Phase C: Brexpiprazole + ADT NCT03538691 · Phase 3 · registry result, not featured evidence · combination 80.6%New Subjects NCT03737474 · Phase 3 · registry result, not featured evidence 38.9%Rollover Subjects NCT03737474 · Phase 3 · registry result, not featured evidence 40.6% NCT01360866 · Phase 3 · registry result, not featured evidence 13.2% NCT01727726 · Phase 3 · registry result, not featured evidence · combination —Brexpiprazole and ADT NCT01838681 · Phase 3 · registry result, not featured evidence —Period B Brexpiprazole and ADT (24 NCT01838681 · Phase 3 · registry result, not featured evidence 33.3%Adjunct Brexpiprazole NCT02400346 · Phase 3 · registry result, not featured evidence · combination —Brex + ADT NCT02400346 · Phase 3 · registry result, not featured evidence · combination — NCT02196506 · Phase 3 · registry result, not featured evidence · combination 38.3% NCT02013609 · Phase 3 · registry result, not featured evidence 6.8% NCT01942733 · Phase 3 · registry result, not featured evidence 7.4% NCT01942785 · Phase 3 · registry result, not featured evidence 13.5% NCT02013531 · Phase 3 · registry result, not featured evidence 11%2 mg NCT03697603 · Phase 2/3 · registry result, not featured evidence 4.8%1 mg NCT03697603 · Phase 2/3 · registry result, not featured evidence — NCT01447576 · Phase 2 · registry result, not featured evidence · combination — NCT01052077 · Phase 2 · registry result, not featured evidence —1.5 ± 0.5 mg high dose NCT00797966 · Phase 2 · registry result, not featured evidence —0.5 ± 0.25 mg low dose NCT00797966 · Phase 2 · registry result, not featured evidence —0.15 mg fixed dose NCT00797966 · Phase 2 · registry result, not featured evidence 0%Brexpiprazole-Cohort 1 NCT01670279 · Phase 1 · registry result, not featured evidence 28.6%Brexpiprazole-Cohort 2 NCT01670279 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —1 mga NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3 show 32 more results—1 mg NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3 —3 mg NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3 —3 mg NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3 —2 mg/Day NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3 4.9% NCT04830215 · Phase 4 · registry result, not featured evidence —Brexpiprazole NCT03149991 · Phase 4 · registry result, not featured evidence —Ketamine/Brexpiprazole Arm NCT03149991 · Phase 4 · registry result, not featured evidence · combination 7.1%Phase A: Brexpiprazole + ADT NCT03538691 · Phase 3 · registry result, not featured evidence · combination —Phase B: Brexpiprazole + ADT NCT03538691 · Phase 3 · registry result, not featured evidence · combination —Phase C: Brexpiprazole + ADT NCT03538691 · Phase 3 · registry result, not featured evidence · combination 58.1%New Subjects NCT03737474 · Phase 3 · registry result, not featured evidence 22.2%Rollover Subjects NCT03737474 · Phase 3 · registry result, not featured evidence 8.6% NCT01360866 · Phase 3 · registry result, not featured evidence — NCT01727726 · Phase 3 · registry result, not featured evidence · combination —Brexpiprazole and ADT NCT01838681 · Phase 3 · registry result, not featured evidence —Period B Brexpiprazole and ADT (24 NCT01838681 · Phase 3 · registry result, not featured evidence 18.2%Adjunct Brexpiprazole NCT02400346 · Phase 3 · registry result, not featured evidence · combination —Brex + ADT NCT02400346 · Phase 3 · registry result, not featured evidence · combination — NCT02196506 · Phase 3 · registry result, not featured evidence · combination 6.4% NCT02013609 · Phase 3 · registry result, not featured evidence — NCT01942733 · Phase 3 · registry result, not featured evidence 3.7% NCT01942785 · Phase 3 · registry result, not featured evidence — NCT02013531 · Phase 3 · registry result, not featured evidence 7.3%2 mg NCT03697603 · Phase 2/3 · registry result, not featured evidence 1.2%1 mg NCT03697603 · Phase 2/3 · registry result, not featured evidence — NCT01447576 · Phase 2 · registry result, not featured evidence · combination — NCT01052077 · Phase 2 · registry result, not featured evidence —1.5 ± 0.5 mg high dose NCT00797966 · Phase 2 · registry result, not featured evidence —0.5 ± 0.25 mg low dose NCT00797966 · Phase 2 · registry result, not featured evidence —0.15 mg fixed dose NCT00797966 · Phase 2 · registry result, not featured evidence 0%Brexpiprazole-Cohort 1 NCT01670279 · Phase 1 · registry result, not featured evidence 14.3%Brexpiprazole-Cohort 2 NCT01670279 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 0.4%1 mga NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3 show 32 more results—1 mg NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3 0.4%3 mg NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3 —3 mg NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3 1.1%2 mg/Day NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3 0% NCT04830215 · Phase 4 · registry result, not featured evidence 0%Brexpiprazole NCT03149991 · Phase 4 · registry result, not featured evidence —Ketamine/Brexpiprazole Arm NCT03149991 · Phase 4 · registry result, not featured evidence · combination 0.9%Phase A: Brexpiprazole + ADT NCT03538691 · Phase 3 · registry result, not featured evidence · combination 1.6%Phase B: Brexpiprazole + ADT NCT03538691 · Phase 3 · registry result, not featured evidence · combination 0.4%Phase C: Brexpiprazole + ADT NCT03538691 · Phase 3 · registry result, not featured evidence · combination 3.2%New Subjects NCT03737474 · Phase 3 · registry result, not featured evidence 3.7%Rollover Subjects NCT03737474 · Phase 3 · registry result, not featured evidence 3.3% NCT01360866 · Phase 3 · registry result, not featured evidence 0% NCT01727726 · Phase 3 · registry result, not featured evidence · combination 2%Brexpiprazole and ADT NCT01838681 · Phase 3 · registry result, not featured evidence —Period B Brexpiprazole and ADT (24 NCT01838681 · Phase 3 · registry result, not featured evidence —Adjunct Brexpiprazole NCT02400346 · Phase 3 · registry result, not featured evidence · combination 4.5%Brex + ADT NCT02400346 · Phase 3 · registry result, not featured evidence · combination 0.5% NCT02196506 · Phase 3 · registry result, not featured evidence · combination 0% NCT02013609 · Phase 3 · registry result, not featured evidence 0% NCT01942733 · Phase 3 · registry result, not featured evidence 0% NCT01942785 · Phase 3 · registry result, not featured evidence 2.7% NCT02013531 · Phase 3 · registry result, not featured evidence 1.2%2 mg NCT03697603 · Phase 2/3 · registry result, not featured evidence 1.2%1 mg NCT03697603 · Phase 2/3 · registry result, not featured evidence 4.2% NCT01447576 · Phase 2 · registry result, not featured evidence · combination 0% NCT01052077 · Phase 2 · registry result, not featured evidence 1.7%1.5 ± 0.5 mg high dose NCT00797966 · Phase 2 · registry result, not featured evidence 0%0.5 ± 0.25 mg low dose NCT00797966 · Phase 2 · registry result, not featured evidence 0%0.15 mg fixed dose NCT00797966 · Phase 2 · registry result, not featured evidence 0%Brexpiprazole-Cohort 1 NCT01670279 · Phase 1 · registry result, not featured evidence 0%Brexpiprazole-Cohort 2 NCT01670279 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 1 mga headache 9.3% (placebo 7.7%) nasopharyngitis 6.6% (placebo 1.8%) weight increased 6.6% (placebo 0.9%) NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3 show 27 more results3 mg akathisia 13.5% (placebo 2.3%) headache 6.1% (placebo 7.7%) somnolence 5.7% (placebo 0.5%) NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3 2 mg/Day weight increased 8% (placebo 3.1%) akathisia 7.4% (placebo 1%) upper resporatory tract infection 3.2% (placebo 6.3%) NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3 fatigue 10.8% headache 10.8% insomnia 10% NCT04830215 · Phase 4 · registry result, not featured evidence alteration in taste 16% (placebo 7.7%) dizziness 16% (placebo 26.9%) restlessness/akathisia 12% (placebo 3.8%) NCT03149991 · Phase 4 · registry result, not featured evidence headache 9.9% (placebo 0%) akathisia 9.6% (placebo 0%) somnolence 7.9% (placebo 0%) NCT03538691 · Phase 3 · registry result, not featured evidence · combination weight increased 15.9% (placebo 5.2%) headache 5.4% (placebo 0%) akathisia 0% (placebo 0%) NCT03538691 · Phase 3 · registry result, not featured evidence · combination weight increased 10.4% (placebo 5.2%) akathisia 0% (placebo 0%) headache 0% (placebo 0%) NCT03538691 · Phase 3 · registry result, not featured evidence · combination akathisia 38.7% tremor 19.4% nasopharyngitis 16.1% NCT03737474 · Phase 3 · registry result, not featured evidence weight increased 36.1% nasopharyngitis 21.8% akathisia 21.3% NCT03737474 · Phase 3 · registry result, not featured evidence weight increased 14.2% (placebo 22.9%) somnolence 8.5% (placebo 7.8%) headache 7.8% (placebo 8.1%) NCT01360866 · Phase 3 · registry result, not featured evidence akathisia 6.1% (placebo 1.9%) headache 5.6% (placebo 4.9%) somnolence 5.6% (placebo 1%) NCT01727726 · Phase 3 · registry result, not featured evidence · combination weight increased 9.5% (placebo 5%) headache 7.7% (placebo 7%) nasopharyngitis 6.3% (placebo 7.7%) NCT01838681 · Phase 3 · registry result, not featured evidence fatigue 15.2% restlessness 12.9% increased appetite 9.8% NCT02400346 · Phase 3 · registry result, not featured evidence · combination akathisia 8.3% (placebo 5%) restlessness 8.3% (placebo 2%) upper respiratory tract infection 5.2% (placebo 5%) NCT02196506 · Phase 3 · registry result, not featured evidence · combination headache 21.3% somnolence 17% weight increased 17% NCT02013609 · Phase 3 · registry result, not featured evidence nausea 13.6% sedation 13.6% headache 11.4% NCT01942733 · Phase 3 · registry result, not featured evidence akathisia 20.4% headache 11.1% dry mouth 7.4% NCT01942785 · Phase 3 · registry result, not featured evidence increased appetite 13.5% diarrhoea 10.8% dizziness 10.8% NCT02013531 · Phase 3 · registry result, not featured evidence 2 mg akathisia 24.4% (placebo 1.2%) weight increased 7.7% (placebo 2.5%) nasopharyngitis 6.5% (placebo 9.8%) NCT03697603 · Phase 2/3 · registry result, not featured evidence 1 mg nasopharyngitis 8% (placebo 9.8%) weight increased 7.2% (placebo 2.5%) tremor 6.4% (placebo 3.7%) NCT03697603 · Phase 2/3 · registry result, not featured evidence weight increased 21% akathisia 9.9% fatigue 9.2% NCT01447576 · Phase 2 · registry result, not featured evidence · combination akathisia 11.9% (placebo 4.8%) weight increased 11.4% (placebo 2.7%) insomnia 9.2% (placebo 3.2%) NCT01052077 · Phase 2 · registry result, not featured evidence 1.5 ± 0.5 mg high dose akathisia 8.3% (placebo 3.2%) diarrhoea 8.3% (placebo 4%) weight increased 7.4% (placebo 0.8%) NCT00797966 · Phase 2 · registry result, not featured evidence 0.5 ± 0.25 mg low dose upper respiratory tract infection 8.3% (placebo 4.8%) headache 7.5% (placebo 9.5%) nasopharyngitis 5.8% (placebo 1.6%) NCT00797966 · Phase 2 · registry result, not featured evidence 0.15 mg fixed dose headache 8.1% (placebo 9.5%) insomnia 8.1% (placebo 3.2%) akathisia 6.5% (placebo 3.2%) NCT00797966 · Phase 2 · registry result, not featured evidence pollakiuria 33.3% (placebo 0%) weight increased 33.3% (placebo 0%) atrioventricular block first degree 16.7% (placebo 0%) NCT01670279 · Phase 1 · registry result, not featured evidence dizziness 50% (placebo 0%) dyspepsia 33.3% (placebo 0%) nausea 33.3% (placebo 0%) NCT01670279 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 28 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Brexpiprazole (Rexulti)
show 71 more results
show 11 more results
show 63 more results
show 60 more results
show 7 more results
show 3 more results
show 59 more results
show 52 more results
show 52 more results
show 50 more results
show 6 more results
show 1 more result
+ 45 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole (Abilify)'s landscape · Brexpiprazole (Rexulti)'s landscape